SPON2

Across TCGA pan-cancer cohorts, SPON2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SPON2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SPON2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPON2 expression acts as an unfavorable survival marker, although some lineages such as OV and UCEC show a favorable association.

PDAC, LUAD, and OV are the cancer types where SPON2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.621	0.878	<.001	42	view →
LUAD	OS	Quartile	All	0.470	0.927	<.001	28	view →
OV	DFS	Median	All	1.000	0.656	.034	4	view →
LSCC	OS	Tertile	All	0.721	0.912	.005	4	view →
GBM	OS	Median	All	0.273	0.513	.022	4	view →
UCEC	DFS	Median	All	1.000	0.939	.030	2	view →
CCRCC	OS	Median	All	1.000	0.892	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SPON2–PDAC (DFS)

Open the PDAC breakdown →